UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _______________ Commission File Number 001-38981 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 83- ...

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Andrew McKibben – Vice President-Investor Relations and Finance Chris Peetz – President and Chief Executive Officer Peter Radovich – Chief Operating Officer Pam Vig – Head-Research and Development Conference Call Participants Steve Seedhouse – Raymond James Mani Foroohar – SVB Leerink Thomas Yip – H.C. Wainwright Operator Good afternoon, and thank you all for joining. I would like to wel ...

$$\begin{matrix} \frac { 3 } { 2 } = - \frac { 3 } { 2 } = - \frac { 3 } { 2 } = - \frac { 3 } { 2 } = - \frac { 3 } { 2 } = - \frac { 3 } { 2 } = - \frac { 3 } { 2 } \end{matrix}$$ Forward-Looking Statements This presentation contains "forward-looking" statements that are based on our management's beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including i ...

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2023 Earnings Conference Call May 6, 2023 4:30 PM ET Company Participants Andrew McKibben - Vice President, Investor Relations and Finance Chris Peetz - President & Chief Executive Officer Peter Radovich - Chief Operating Officer Pamela Vig - Head of R&D Conference Call Participants Mani Foroohar - SVB Securities Ryan Deschner - Raymond James Operator Operator Ladies and gentlemen, welcome to the Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _______________ Commission File Number 001-38981 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 83 ...

Mirum Pharmaceuticals, Inc. (MIRM) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Corporate Participants Andrew McKibben - Vice President, Investor Relations and Finance Chris Peetz - President and Chief Executive Officer Ian Clements - Chief Financial Officer Peter Radovich - Chief Operating Officer Pamela Vig - Head of R&D Conference Call Participants Jessica Fye - JPMorgan Mani Foroohar - SVB Securities Josh Schimmer - Evercore Ryan Deschner - Raymond James David Lebowitz - Citi Brian Skorney ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38981 Mirum Pharmaceuticals, Inc. (Exact name of Registrant as specified in its Charter) Delaware 83-1281555 (State or other jurisdic ...

Corporate Presentation January 2023 Forward-Looking Statements $$\begin{array} { l } { { \mathrm { a n d } } \left[ \begin{matrix} { \mathrm { a n d } \mathrm { a n d } \mathrm { a n d } \mathrm { a n d } \mathrm { a n d } \mathrm { a n d } \mathrm { a n d } \mathrm { a n d } \mathrm { a n d } \mathrm { a n d } \mathrm { a n d } \mathrm { a n d } \mathrm { a n d } \mathrm { a n d } \mathrm { a n d } \mathrm { a n d } \mathrm { a n d } \mathrm { a n d } \mathrm { a n d } \mathrm { a n d } \mathrm { a n d } \ ...

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q3 2022 Results Conference Call November 9, 2022 8:00 AM ET Company Participants Ian Clements - CFO Chris Peetz - President, CEO & Director Peter Radovich - COO Pamela Vig - Head of R&D Richard Thompson - Professor, King's College London Conference Call Participants Jessica Fye - JPMorgan Steve Seedhouse - Raymond James Mani Foroohar - SVB Securities David Lebowitz - Citi Yasmeen Rahimi - Piper Sandler Thomas Yip - H.C. Wainwright Operator Hello, everyone, and welco ...

Corporate Presentation September 2022 Forward-Looking Statements This presentation contains "forward-looking" statements that are based on our management's beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our business strategy, objectives and opportunities. Forward- looking statements are subject to known and unknown risks, u ...